---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-081948"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:37:45.765413+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# BiomX provides pipeline update: BX004 Ph2b results in Q3 2025, BX211 Ph2 results in Q1 2025

## Summary
- BX004 for CF: Phase 2b topline results expected Q3 2025 (60 patients, 2:1 randomized).
- BX211 for DFO: Phase 2 topline results expected Q1 2025 (week 26) and Q1 2026 (week 52).
- Cash and cash equivalents $32.7M as of June 30, 2024.
- Presentation highlights: 14.3% of BX004 patients converted to PsA-negative sputum in Ph1b/2a Part 2.
- Peer phage therapy momentum cited: >100 compassionate use cases with 77% clinical improvement.

## SEC filing metadata
- accession: 0001213900-24-081948
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390024081948/0001213900-24-081948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390024081948/ea0215609-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-081948
- JSON: https://secwatch.observer/filing/0001213900-24-081948.json
- Plain text: https://secwatch.observer/filing/0001213900-24-081948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.